This Company Leads The Way In Cannabinoid Treatment Innovation With New Patent

SciSparc Ltd. SPRC announced on Tuesday that the European Patent Office has granted it a new patent.

The European Application No. 16786064.2 - titled Combinations of Cannabinoids and N-Acylethanolamines - aligns with the company's objective to increase the safety of cannabinoid treatments while maintaining their therapeutic effects.

The Israel-based company was granted the patent in the United States, Japan and Australia.

The patent relates to compositions and methods for potentiating therapeutic effects and/or reducing side effects of selected cannabinoids of the cannabis plant. It also provides pharmaceutical compositions comprising cannabinoids and N-acyl ethanolamines and methods for their use in various indications amenable to treatment with cannabinoids.

"SciSparc's assets continue to expand, both intellectual property alongside revenue generating assets," said Oz Adler, SciSparc's CEO. "The company continues to lead in this space with a robust IP portfolio worldwide. We continue to believe that cannabinoid-based medicines have enormous therapeutic potential and therefore, we continue to strengthen the patent protection around the technologies we develop".

SPRC Price Action

SciSparc's shares traded 37.06% higher at $5.04 per share at the time of writing on Tuesday morning.

Related News

• Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed
• SciSparc To Conduct Clinical Trial For Dronabinol-Based Drug To Treat Tourette Syndrome In Germany
• EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US

Photo: Courtesy of CBD Infos on Unsplash